Drug Trial Radar · NCT06996912
A Study for HSK44459 in Participants With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Jan 20, 2026
Study completion Mar 23, 2026
Sponsor
- Lead sponsor
- Xizang Haisco Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis
Conditions
- Atopic Dermatitis (AD)
Interventions
HSK44459Drug
HSK44459 will be administered orally twice daily
PlaceboDrug
Placebo will be administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline to week 12 in EASITime frame: From Day 1 (first dose) to Day 85 (week 12)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Dermatology Hospital of Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.